Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions

Core Insights - Glucotrack's Continuous Blood Glucose Monitor (CBGM) technology has demonstrated safety and accuracy with a Mean Absolute Relative Difference (MARD) of 7.7% in a first-in-human clinical study [1][2][5] Study Results - The clinical study met all primary and secondary endpoints, achieving a 99% data capture rate and no serious adverse events related to the procedure or device [2][4] - Analysis showed that 92% of CBGM measurement values were in the green zone according to the Diabetes Technology Society Error Grid, indicating high clinical accuracy [3] Technology Overview - The CBGM is a fully implantable system that measures glucose directly from blood, eliminating lag time associated with traditional interstitial fluid monitors [6] - Designed for a three-year sensor life, the system requires minimal calibration and has no on-body wearable component, offering a less intrusive solution for diabetes management [6][11] Future Plans - Glucotrack plans to initiate a long-term early feasibility study in Q3 2025 to further evaluate the safety and performance of the CBGM technology [5]